Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...
Key Takeaways Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be ...
Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...
Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...
Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...